Edgar Filing: NephroGenex, Inc. - Form 4

NephroGene Form 4	ex, Inc.									
May 16, 201							OMB A	APPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								3235-0287		
if no long subject to Section 1 Form 4 c	Check this box if no longer subject to Section 16. Form 4 or						burden ho response.	urs per		
Form 5 obligatio may com <i>See</i> Instr 1(b).	tinue. Section 17	(a) of the P		olding Co	mpany Act	nge Act of 1934, of 1935 or Section 940				
(Print or Type]	Responses)									
1. Name and Address of Reporting Person <u>*</u> Seltzer Robert R.			2. Issuer Name a Symbol			5. Relationship of Reporting Person(s) to Issuer				
(Last)	(First) (NephroGenex, 3. Date of Earlies	_	-	(Check all applicable)				
	ROGENEX, INC XANDER DRIVE	., 79	(Month/Day/Year 05/15/2014			X Director Officer (giv below)		0% Owner her (specify		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting				
RESEARCI PARK, NC	H TRIANGLE 27709					Person	wore than one r	ceponing		
(City)	(State)	(Zip)	Table I - No	n-Derivative	Securities A	Acquired, Disposed	of, or Beneficia	ally Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution I any	Date, if Transac Code //Year) (Instr. 8	 4. SecuritionAcquired Disposed (Instr. 3, V Amount 	(A) or of (D) 4 and 5) (A) or	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Rep	port on a separate line	e for each cla	ss of securities be	-	-	-				
				inforr requi	nation cont red to resp ays a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab		ative Securities A outs, calls, warra		-	Beneficially Owned securities)	1			
Derivative		nsaction Date n/Day/Year)	3A. Deemed Execution Date, any	4. if Transac Code	5. Numbe ctionof Deriva Securities	tive Expiration Dat	e	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. D Se	

Edgar Filing: NephroGenex, Inc. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A) or Disposed (D) (Instr. 3, and 5)	d of				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Common Stock	\$ 11.9	05/15/2014 <u>(1)</u>		A		3,076		(2)	02/13/2024	Common Stock	3,076

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Seltzer Robert R. C/O NEPHROGENEX, INC. 79 T.W. ALEXANDER DRIVE RESEARCH TRIANGLE PARK, NC 27709	Х	Х				
Signatures						
/s/ Pierre Legault as						

/s/ Pierre Legault, as	
attorney-in-fact	05/16/2014

**Signature of Reporting Person

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The option grant was approved by NephroGenex, Inc.'s board of directors on February 14, 2014, subject to shareholder approval of an

- (1) amendment to the stock option plan under which the option was granted. NephroGenex, Inc.'s shareholders approved the amended plan on May 15, 2014.
- 25% of the option vests on February 14, 2015 and 2.0833% of the option will vest on a monthly basis in each of the following 36 months (2)thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(Iı